Enovis and Ossium to Distribute OssiGraft and OssiGraft Prime

Enovis has entered a strategic partnership with Ossium Health, a clinical-stage biotechnology company, to distribute OssiGraft and OssiGraft Prime through Enovis’ extensive sales network. 
 
The OssiGraft and OssieGraft Prime are cryopreserved viable bone matrix (VBX) allografts consisting of 100% viable bone in a demineralization-free solution, with 80% cancellous bone. This composition optimizes bone healing as research suggests the cancellous bone enables faster revascularization in just two weeks, compared to the two-month process required for cortical bone.^1,2 With an average donor age of 35, OssiGraft and OssiGraft Prime deliver remarkable biological vitality, allowing them to compete with competitors in efficacy^3,4.
 
“Our newly forged alliance with Ossium Health enriches our portfolio with invaluable allograft solutions,” said Gary Justak, President and General Manager of Enovis Foot & Ankle. “By integrating these premium grafts into our distribution network, we are expanding our capacity to provide surgeons with advanced products that redefine surgical results and elevate patient care.”
 
To meet this mechanical stability demand, the Enovis product portfolio provides a comprehensive selection of carefully engineered solutions, such as the DynaNail TTC Fusion System, which uses sustained dynamic compression technology. When structural reinforcement and biological foundation combine, patients experience a seamless recovery process from successful fusion.
 

References: 

¹ Kumagai, K. et al. 2008. J. Ortho. Res. / Liu, R. et al. 2011. BMC Muscuskelet. Disord. / Neagu, T. et al. 2016. Rom. J. Morphol. Embryol. Rabie, A. B., et al. 1996. Int. J. Oral Maxillofac. Surg. /Colnot, C. 2009. J. Bone Miner. Res. / Suh, K.T. et al. 2012. J. Magn. Reson. Imaging / Siclari, V.A. et al. 2013. Bone 53, 575-586.
² Bell, G et al. 2005. Spine Surgery (Bone Graft harvesting).
³ Becker’s Spine Review. (2023, September 20). OssiGraft Prime used in first orthopedic case.
⁴ Chen, T. et al. 2018. Sci. Res.